TELA BIO, INC.— Sankey Diagram
Quarterly mode · period ending 2025-12-31 · SEC EDGAR
ComparingFY2025 (Q4) vs FY2024 (Q4)
Revenue
$21M
↑+18.2% +$3Mvs FY2024 (Q4)
Gross Profit
$14M
↑+22.5% +$3Mvs FY2024 (Q4)
Operating Income
$11M
↑+28.3% +$2Mvs FY2024 (Q4)
Net Income
$9M
↑+26.4% +$2Mvs FY2024 (Q4)
Click a Metric or Sankey Node to View Historical Trends
Show Source Data (Audit Panel)
| Line item | FY2025 (Q4) | FY2024 (Q4) |
|---|---|---|
| Revenue | $21M | $18M |
| COGS | $7M | $6M |
| Gross Profit | $14M | $11M |
| R&D | $2M | $2M |
| SG&A | $0 | $0 |
| D&A | $130K | $171K |
| Other OpEx | $277K | $285K |
| Operating Income | $11M | $9M |
| Interest Exp. | $2M | $1M |
| Other Non-Op | $0 | $0 |
| Pretax Income | $10M | $8M |
| Tax | $145K | $0 |
| Net Income | $9M | $8M |
QuarterCharts · SEC EDGAR data · TELA · Comparing FY2025 (Q4) vs FY2024 (Q4)